Demonstrated safety and efficacy in MOSAIC, a randomized clinical trial in patients undergoing Mohs surgery.
Tempo’s first-in-human study compared MAP™ with standard care in patients with full-thickness wounds after Mohs surgery for non-melanoma skin cancer.
- Design
- Randomized, controlled, multicenter
- Patients
- 40
- Setting
- Full-thickness wounds after Mohs surgery for non-melanoma skin cancer
- Control
- Hydrocolloid standard of care
- Safety
- Met the primary safety endpoint, with no serious adverse device effects, infections or delayed wound healing reported
- Registry
- NCT06600152
- Safetyprimary endpoint met
- Day 0
Surgery and MAP™ applied
- Healing14days earlier
to a favorable wound bed score
- Follow-up6months
improved physician-assessed scar quality
Improved scar quality, fewer interventions
At about six months, MAP™-treated wounds showed significantly better physician-assessed scar quality and less soft tissue volume loss than standard hydrocolloid care.
Each dot represents about 5% of patients; dot counts are rounded to the nearest 5%. Figures from Tempo’s August 2026 company presentation.

“Mohs surgery can be lifesaving, but the healing process—and concerns about scarring—can be difficult for patients. There remains a substantial need for new approaches that help restore tissue after cancer removal. Tempo’s MAP™ technology, being evaluated in the MOSAIC study, offers a promising approach to addressing that need. For dermatologic surgeons, the goal extends beyond removing the cancer: it is also about giving patients a softer landing through healing and recovery.”Samuel Broder, M.D.Director, National Cancer Institute (retired)
The next randomized study.
MOSAIC II will evaluate whether MAP™ reduces the time needed to develop a wound bed suitable for grafting after complex non-melanoma skin cancer resections with exposed bone. It is supported by an SBIR award from the National Cancer Institute of approximately $2.25 million over two years. Principal investigator: Stephanie Deshayes, PhD.
The science behind MAP™.
Follow the founders’ ongoing work at the Griffin Lab and the Segura Lab.
- RESEARCH PUBLICATION
Cellular Architects at Work: Cells Building their Own Microgel Houses
Advanced Healthcare Materials ↗ - RESEARCH PUBLICATION
A Novel Microporous Biomaterial Vaccine Platform for Long-Lasting Antibody Mediated Immunity Against Viral Infection
PubMed ↗ - RESEARCH PUBLICATION
De novo tissue formation using custom microporous annealed particle hydrogel provides long-term vocal fold augmentation
npj Regenerative Medicine ↗ - RESEARCH PUBLICATION
Activating an adaptive immune response from a hydrogel scaffold imparts regenerative wound healing
Nature Materials ↗ - RESEARCH PUBLICATION
Injectable Drug-Releasing Microporous Annealed Particle Scaffolds for Treating Myocardial Infarction
Advanced Functional Materials ↗ - RESEARCH PUBLICATION
Injection of Microporous Annealing Particle (MAP™) Hydrogels in the Stroke Cavity Reduces Gliosis and Inflammation and Promotes NPC Migration to the Lesion
Advanced Materials ↗ - RESEARCH PUBLICATION
Accelerated wound healing by injectable microporous gel scaffolds assembled from annealed building blocks
Nature Materials ↗